- A	Specimen	Status	Location	Conc	Date	Toolse	1						
av	Inf305-8	SMZV	Box 9 A	Conc	2019-09-	Tasks	Volume	Ly	Ly+Mon	Total	1E+6	1.5E+6	400
esyl	2-2 (7)	HU	E, S		30	600K	2	10E6	125EG	20 M		ISON	4
bought	Inf 185mg	SCFB	Box 5000 7A		2012 12								'
	Inf 1857 229-3 (8)			I I	2019-04-		2	4.49 E6	6.79 EG	8.8 M		334 N	\sim
8100/1	Inf314-8 2-2 (9)	SNHB	Box WA,		2019-11-	1.5=11.2M		LF	·			331P	
60/1	2-2 (9)	HEO-H	B, 7		05		2	7.45 E6	9.33 E6	149M		2011	53
250gr	NDOSO	Adult		ISE 6	08/24/21	.5 = 1.7M	^		4.31 E6		11211	.,,,	- '
-cup1		. 10			-0,-421		2	3.51 E6	4.31 E6	7.02	113 1/1		×

	Ex vivo Gd-p4b				ntra x 3
BV421	PD1	2	6	μL	
BV510	Aqua L/D	1:500			
BV650	CD56	1.8	5.4		
Alexa 488 (FITC)	Perforin (dG9)	-	-	3	9
PerCPeF710	CD3	1.5	4.5		
PE	GZMb		-	1.5	20.7
PE Dazzle				1.5	4.5
PE Vio770	NKG2A	0.6	1.8		
APC	V82	1	3		
APC Fire750	CD16	1	3		
20.5 μl/rxn;	PBS	12.6	37.8	16.0	52.5

	Ex vivo Gd-CK PMA	Sur µL	face x 6	In µL	itra x 6
BV421	PD1	2	12		
BV510	Aqua L/D	1:500			
BV650	CD27	1.5	9		
FITC	Vδ2	1.2	7.2	0.2	1. 2
PerCPeF710	CD3	1	6	0.2	1. Z
PE	CD56	0.5	3	·	1
PE Dazzle					
PE Vio770	IFNγ		-	0.6	3.0
Alexa 647 (APC)	TNFα	-	-	2	17
APC Fire750	CD45RO	2	12		
20.5 μl/rxn;	PBS	12.3	73.8	17.5	105

	Ex vivo Gd-p1	Sur µL	face
V450 BV421	PD1	2	6
V525 BV510	Aqua L/D	1:500	
V670 BV650	CD16	1.5	4.5
B530 FITC	V82	1.2	3.6
B710 PerCPeF710	CD25	2	6
Y590 PE	CD28	2	6
Y615 PE Dazzle	CD27	1.5	he. 5
Y780 PE Vio770	CD3	0.5	1.5
R670 APC	Vδ1	1	3
R780 APCFire750	CD45RA	1.8	5.4
20.5 μl/rxn;	PBS	7	21

	Ex vivo Gd-p2	Surf µL	ace x 3	In μL	tra x 3
BV421	V82	1	3		
BV510	CD3	1.5	4.5		1
BV650	NKG2D	2	6		-
B v 050	Streptavidin	{1.5}			+
Alexa 488 (FITC)	dg9	-		3	9
PerCPVio700	CD56	1	3		
PE	PD1	1.5	4.5		
PE Dazzle			(-,-)		
PE Vio770	NKG2A	0.6	1.8		
APC	V81	1	3		
APC Fire750	Horizon L/D	1:1000			
20.5 μl/rxn;	PBS	11.9	35.7	17.5 2m(FBS	52.5

324 WOAm 122 20pl -240pl

3 ml - 3 pl 4/0

53 19.5

6:58 2ml FBS wash 1,0 7:10-7 20-7 330 x 6 Rbclysce

90 7:32->35


FIXPERM Pr/Pribe 440

Interpres:15 P46 do 4.06:04

FirPam@7.46px chil 305 + . 8 mit

Intrace 8:26 6:39 Youdded C 6:46


Dune @ 9:17 pm



-	Specimen	Status	Location	Conc	Date	Tasks	W7 V					3516	
17.		SMZU		John	Date	Tasks	Volume	Ly	Ly+Mon	Total		1.5E+6	7
	Inf305-8	4 -				mort	2	10E6	12.5E6	20 M		24000	1.7
15 = 11.1	To 0000 0	SCFA											
600 4/1	Inf219-3					×	2	4.17 E6	6.73 E4	8.34	1.5 = 3604	4 Coul	1.5
	T-0314	SUHA										ts	100
8400/1	Inf314 a-1	HEU-h				58 pl	2	6.92 E6	8,94 E4	13.8M		340W	1.66
												+6	100
-						· ·		351 E6				3504 650	1.65
		* x											
L													
	al a												

17.4 + 20 = 37.4 - 13.5 = 23.9 6.46 + 8.8 = 15.26 - 13.5 = 1.76 11.49 + 14.9 = 26.39 - 13.5 = 12.89 $5.79 = 400 \text{ placker scs} \rightarrow 1 \text{ tube}$

×30 12.0



	Ex vivo MAIT-p1a	Sui µL	rface 3
V450 BV421	Va7.2	2	6
V525 BV510	Aqua L/D	1:500	-
V670 BV650			
B530 FITC	CD4	1.8	5.4
B710	CD 45D +		
PerCPeF710	CD45RA	2	6
Y590 PE	CD161	0.5	1.5
Y615 PE Dazzle	CCR7	1.5	453
Y780 PE Vio770	CD3	0.5	1.5
R670 APC	CCR6	2.5	7.56
R780 APCFire750	CD8	1.5	4.5
20.5 μl/rxn;	PBS	8.2	24.6

360 H FAZZ9 NOUTS

	Ex vivo MAIT-p1a	Su µL	rface 3
V450 BV421	CCR6	2	0/5
V525 BV510	Aqua L/D	1:500	-
V670 BV650			
B530 FITC	CD4	1.8	5.4
B710 PerCPeF710	CD45RA	2	6
Y590 PE	CD161	0.5	1.5
Y615 PE Dazzle	CCR7	1.5	453
Y780 PE Vio770	CD3	0.5	1.5
R670 APC	hMR1	(:16) 5pl	-
R780 APCFire750	CD8	1.5	4.5
20.5 μl/rxn;	PBS	10.7	32.1

	Ex vivo NKT-p1a	Sui µL	face 3
V450 BV421	Va24	1.2	x 425
V525 BV510	Aqua L/D	1:500	3.6
V670 BV650	NKG2D	1	3
B530 FITC	CD4	1.8	5.4
B710 PerCPeF710	CD45RA	2	6
Y590 PE	CD161	0.5	1.8/
Y615 PE Dazzle	CCR7	1.5	4.50
Y780 PE Vio770	CD3	0.5	1.5
R670 APC	CCR6	2.5	256
R780 APCFire750	CD8	1.5	4.5
20.5 μl/rxn;	PBS	8	24

185 Hours

	Ex vivo NKT-p1a	Sui µL	rface3
V450 BV421	CCR6	2	65
V525 BV510	Aqua L/D	1:500	-
V670 BV650	NKG2D	1	3
B530 FITC	CD4	1.8	5.4
B710 PerCPeF710	CD45RA	2	6
Y590 PE	CD161	0.5	1.5
Y615 PE Dazzle	CCR7	1.5	453
Y780 PE Vio770	CD3	0.5	1.5
R670 APC	hCD1d	1:10 (1.5)	-
R780 APCFire750	CD8	1.5	4.5
20.5 μl/rxn;	PBS	9.7	29.1

